See other companies on Welcome to the Jungle

OneStudyTeam

Digital tools for clinical trials

OneStudyTeam logo
201-500 employees
  • Healthcare
  • B2B
  • SaaS
  • Social Impact
  • MedTech
Downtown Crossing, Boston, MA

Company mission

To pave the way to faster, predictable, and more accessible clinical trials.

Top investors

-34% employee growth in 12 months

Our take

Clinical research remains a significant bottleneck on drug development. Much of this is due to the slow and unpredictable nature of patient enrolment. OneStudyTeam is tackling this problem with a platform that helps biopharma companies and research sites to enroll trials in three to four months instead of 18 months.

The company's tools are already being used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly & Company, and across a total of over 5,000 research sites across 65 countries. In 2022, OneStudyTeam invested $220 million into improving diversity in clinical trials. This is a strong indicator of the company’s future-facing outlook and its impressive financial backing.

The business is scaling fast, reaching Unicorn status with its Series C round in 2021. If this trajectory continues, OneStudyTeam could become one of the leading names in the pharmaceutical and healthcare industries.

Kirsty headshot

Kirsty

Company Specialist at Welcome to the Jungle

Benefits

  • Comprehensive health and wellness
  • Flexible paid time off
  • Generous parental leave
  • 401(k) company match

Funding (last 2 of 5 rounds)

Apr 2022

$220m

SERIES D

Aug 2021

$220m

SERIES C

Total funding: $477.6m

This company has top investors

Leadership

Founded Reify Health in 2012 whilst completing a PhD/MD at The Johns Hopkins University School of Medicine. Also Co-Founder and Board Member at Signal Vine.

Michael Lin

(Executive Chairman)

Studied at The Johns Hopkins University School of Medicine. Also Co-founder at Signal Vine.